drug
dulaglutide
Marketedupdated 3mo agoby Eli Lilly and Co
Approvedannual revenue · 2024–2024peak $5.3B
community read0 votes
🐶 often sniffed alongside
top 3Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for diabetes mellitus and type 2 diabetes mellitus and 4 investigational indications.
indications
investigational
Type 2 Diabetes
all catalysts(22)
approval · 22
Sep 18, 2014
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Dec 19, 2014
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Mar 9, 2015
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Jul 27, 2015
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Jan 27, 2017
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Jan 27, 2017
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Aug 1, 2017
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Aug 1, 2017
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Dec 12, 2017
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Jun 29, 2018
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Sep 21, 2018
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Jan 15, 2019
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Feb 21, 2020
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Sep 3, 2020
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Sep 30, 2021
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Jun 10, 2022
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Jun 10, 2022
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Nov 17, 2022
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Nov 1, 2024
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Nov 1, 2024
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
May 28, 2025
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Mar 12, 2026
approval
$LLY1180.16-2.25%
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Trials studying dulaglutide
- phase3A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
- phase3A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- phase1A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus
- phase3A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
- phase3A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
- phase3A Phase 3 Study of HS-20094 in Patients With T2DM
- phase3A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
- phase2A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 14m ago
Found something off?
comments(0)
5-min edit window · permanent after that